Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA rejects expanded use of Amarin's Vascepa

This article was originally published in Scrip

Executive Summary

Shares of Amarin tumbled about 10% on 28 April after the company disclosed the FDA declined to expand the use of Vascepa (icosapent ethyl) in the US as an adjunct to diet to reduce triglyceride (TG) levels in adults on statin therapy with mixed dyslipidemia and TG levels from 200mg/dL to 499mg/dL – the so-called ANCHOR indication.

Related Content

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts